NSPR · InspireMD, Inc.

The price reported is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $0.87 to $0.88. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person.

The price reported is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $1.00 to $1.04. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

The price reported is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $1.1550 to $1.1599. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

This Form 4/A is being filed solely to reflect that the reported transactions were not effected pursuant to a Rule 10b5-1(c) trading plan. The Form 4 filed on May 12, 2026 (the "Original Filing") inadvertently checked the box that the transactions were effected pursuant to a Rule 10b5-1(c) trading plan. The Reporting Person does not currently maintain any Rule 10b5-1 trading plans. The transaction details otherwise reported in the Original Filing remain accurate and unchanged.

The price reported is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $1.17 to $1.20. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

This Form 4/A is being filed solely to reflect that the reported transactions were not effected pursuant to a Rule 10b5-1(c) trading plan. The Form 4 filed on May 12, 2026 (the "Original Filing") inadvertently checked the box that the transactions were effected pursuant to a Rule 10b5-1(c) trading plan. The Reporting Person does not currently maintain any Rule 10b5-1 trading plans. The transaction details otherwise reported in the Original Filing remain accurate and unchanged.

The price reported is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $1.15 to $1.16. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

The Form 4 filed on August 1, 2025 (and subsequent Form 4s reflecting this information) inadvertently reported that 20,661 shares of common stock purchased on July 30, 2025 were indirectly held by the Reporting Person through Osiris Investment Partners, L.P. ("Osiris"). However, such shares were held directly by the Reporting Person. After adjusting for the foregoing and further technical adjustments, the Reporting Person (i) directly beneficially owned 557,245 shares of Common Stock and (ii) indirectly, through Osiris, beneficially owned 423,704 shares of Common Stock, in each case immediately prior to the transaction reported herein.

This Form 4 reflects the Reporting Person's correct beneficial ownership following the transaction reported herein. No change in the Reporting Person's pecuniary interest resulted from these corrections.

The price reported is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $1.14 to $1.15. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

The price reported is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $1.15 to $1.20. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

The price reported is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $1.13 to $1.15. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person.

The sales reported on this Form 4 represent shares of common stock required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the reporting person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the reporting person.

The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person.

The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person.

The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person.

The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person.

The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person.

The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person.

The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person.

The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person.

The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person.

These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service.

These restricted stock units vest and become exercisable in three equal annual installments, with 1/3 vesting on each of January 14, 2027, January 14, 2028 and January 14, 2029, subject to the Reporting Person's continued service.

These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of January 14, 2027, January 14, 2028 and January 14, 2029, subject to the Reporting Person's continued service.

These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service.

These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service.

These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service.

These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service.

These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service.

These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of January 14, 2027, January 14, 2028 and January 14, 2028, subject to the Reporting Person's continued service.

These shares of common stock represent shares of restricted stock, which vest and become exercisable in three equal annual installments, with 1/3 vesting on each of January 14, 2027, January 14, 2028 and January 14, 2029, subject to the Reporting Person's continued service.

Represent grant of shares of common stock and options to purchase shares of common stock for services rendered as a director of the Issuer in 2025 prior to the Reporting Person's resignation as a director, effective December 31, 2025.

Represent grant of shares of common stock and options to purchase shares of common stock for services rendered as a director of the Issuer in 2025 prior to the Reporting Person's resignation as a director, effective December 31, 2025.

This Form 4/A amends the Form 4 filed on December 11, 2025 solely to correct the number of shares reported in Table I, Column 4. The number of shares reported in Column 5 was correct as originally filed. No other changes have been made.

The price reported is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $1.80 to $1.81. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

These shares of common stock represent shares of restricted stock that shall vest on October 7, 2026 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service.

Represent grant of shares of common stock for services rendered as a director of the issuer in 2025 prior to the Reporting Person's resignation as a director, effective September 16, 2025.

The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on July 30, 2025 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement").

The purchase price per share of common stock in the Private Placement was $2.42.

The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on July 30, 2025 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement").

The purchase price per share of common stock in the Private Placement was $2.42.

The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on July 30, 2025 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement").

The purchase price per share of common stock in the Private Placement was $2.42.

The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on July 30, 2025 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement").

The purchase price per share of common stock in the Private Placement was $2.42.

These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.